Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Development of viral vectors capable of transducing photoreceptors by less invasive methods than subretinal injection would provide a major advancement in retinal gene therapy. We sought to develop novel AAV vectors optimized for photoreceptor transduction following intravitreal delivery and to develop methodology for quantifying this transduction in vivo. Surface exposed tyrosine (Y) and threonine (T) residues on the capsids of AAV2, AAV5 and AAV8 were changed to phenylalanine (F) and valine (V), respectively. Transduction efficiencies of self-complimentary, capsid-mutant and unmodified AAV vectors containing the smCBA promoter and mCherry cDNA were initially scored in vitro using a cone photoreceptor cell line. Capsid mutants exhibiting the highest transduction efficiencies relative to unmodified vectors were then injected intravitreally into transgenic mice constitutively expressing a Rhodopsin-GFP fusion protein in rod photoreceptors (Rho-GFP mice). Photoreceptor transduction was quantified by fluorescent activated cell sorting (FACS) by counting cells positive for both GFP and mCherry. To explore the utility of the capsid mutants, standard, (non-self-complementary) AAV vectors containing the human rhodopsin kinase promoter (hGRK1) were made. Vectors were intravitreally injected in wildtype mice to assess whether efficient expression exclusive to photoreceptors was achievable. To restrict off-target expression in cells of the inner and middle retina, subsequent vectors incorporated multiple target sequences for miR181, an miRNA endogenously expressed in the inner and middle retina. Results showed that AAV2 containing four Y to F mutations combined with a single T to V mutation (quadY-F+T-V) transduced photoreceptors most efficiently. Robust photoreceptor expression was mediated by AAV2(quadY-F+T-V) -hGRK1-GFP. Observed off-target expression was reduced by incorporating target sequence for a miRNA highly expressed in inner/middle retina, miR181c. Thus we have identified a novel AAV vector capable of transducing photoreceptors following intravitreal delivery to mouse. Furthermore, we describe a robust methodology for quantifying photoreceptor transduction from intravitreally delivered AAV vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [95]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSelf-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Clinical trials for RPE65-Leber congenital amaurosis (LCA) have demonstrated the ability to deliver therapeutic transgene to the retinal pigment epithelium (RPE) by subretinal injection thereby restoring retinal function and visually-evoked behavior to patients [1–3].”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 7×
“In primate, the ILM is significantly thicker, except for an area in and around the fovea and immediately above large blood vessels [56].”
BackgroundInfluentialGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“Several serotypes have been used to successfully target transgene to PRs following subretinal injection, including AAV2, AAV5 and AAV8 with all three demonstrating efficacy in proof of concept experiments across multiple species (mouse, rat, dog, pig and non-human primate) [8–21].”
MethodSelf-citation(1984) · PubMed · Cited by 1,200
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“Adeno-associated virus (AAV) is considered the optimal vector for ocular gene therapy due to its efficiency, persistence and low immunogenicity [7].”
BackgroundRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741 · cited 1×
“Promoter constructs were identical to those previously described [31,33,34].”
ResultJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639 · cited 1×
“reported that subretinal injection under a cone-rich fovea resulted in decreased visual acuity (in some LCA2 patients) and foveal thinning (in both LCA2 patients and non-human primates) [5,6].”
BackgroundPhotoreceptor degeneration: genetic and mechanistic dissection of a complex trait
Wright, A. F., Chakarova, C. F., Abd El-Aziz, M. M., & Bhattacharya, S. S. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2717 · Cited by 631 · cited 1×
“Given the predominance of photoreceptor (PR) specific retinal degenerations [4], there is a need to develop PR targeted gene therapies.”
Background
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“The capsid choice in this trial was dictated by transduction observed in the XLRS mouse model and perhaps the expectation that the presence of schisis cavities in XLRS patient retinas would facilitate transduction.(128) Taken together, the lack of efficacy in this trial was at least partially due to inefficient target…”
BackgroundSelf-citationAAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Progresses towards safe and efficient gene therapy vectors
Chira, S., Jackson, C. S., Oprea, I., Ozturk, F., Pepper, M. S., Diaconu, I., Braicu, C., Raduly, L.-Z., Calin, G. A., & Berindan-Neagoe, I. (2015) · Oncotarget · doi:10.18632/oncotarget.5169 · Cited by 219
“Optimal transduction efficiency can further be obtained through combinational mutagenesis of the surface-exposed Y and T residues [115] [116].”
BackgroundMacé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.-A., Picaud, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.154 · Cited by 197
“To overcome these hurdles, new AAV variants with the ability to deliver genes deep into the retina via intravitreal route have been engineered 20-22 .”
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“5-fold increase in PR transduction efficiency after intravitreal injection (Kay et al., 2013).”
BackgroundInfluentialSengupta, A., Chaffiol, A., Macé, E., Caplette, R., Desrosiers, M., Lampič, M., Forster, V., Marre, O., Lin, J. Y., Sahel, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505699 · Cited by 180
“AAVs were pseudotyped with AAV2 and AAV8 Y447 733F capsids (Kay et al, 2013) for the hSyn and CAG constructs, respectively.”
Wassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A. (2017) · Scientific Reports · doi:10.1038/srep45329 · Cited by 164
Restoring Vision to the Blind with Chemical Photoswitches
Tochitsky, I., Kienzler, M. A., Isacoff, E. Y., & Krämer, R. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00723 · Cited by 171
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“Indeed, mutating several surface exposed tyrosine and threonine residues signifi cantly increased the transduction effi ciency of AAVs 2, 5, and 8 [ 111 , 112 ].”
BackgroundThe Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
“It is thus exciting that experiments using either directed evolution or generating specific capsid mutations have led to vectors that can target the outer retina after intravitreal injection (Dalkara et al. 2013; Kay et al. 2013).”
BackgroundEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Let There Be Light: Gene and Cell Therapy for Blindness
Dalkara, D., Goureau, O., Marazova, K., & Sahel, J.-A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.147 · Cited by 129
“24,25 Implementation of gene therapy for other inherited retinal diseases Today, gene therapy is being implemented for other retinal degenerative diseases.”
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Journey to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Slijkerman, R. W. N., Song, F., Astuti, G., Huynen, M. A., van Wijk, E., Stieger, K., & Collin, R. W. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.004 · Cited by 135
“A different approach, again using capsid-modified variants where tyrosine or phenylalanine residues were mutated, likewise yielded AAV capsid mutants able to transduce photoreceptors following intravitreal injection in mice (Kay et al., 2013).”
BackgroundRetinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
“Ongoing improvements in vector design could help overcome those limitations and potentially make IVT both safe and efficient option for gene therapy over the long run (Dalkara et al., 2013; Kay et al., 2013).”
BackgroundThe primate model for understanding and restoring vision
Picaud, S., Dalkara, D., Marazova, K., Goureau, O., Roska, B., & Sahel, J.-A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902292116 · Cited by 113
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
Garanto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 110
“And although with current approaches, only part of the retina is targeted, new subclasses of AAVs are currently being developed that might allow a more effective targeting of the outer retina after intravitreal injection (49,50).”
BackgroundHuman Cone Visual Pigment Deletions Spare Sufficient Photoreceptors to Warrant Gene Therapy
Cideciyan, A. V., Hufnagel, R. B., Carroll, J., Sumaroka, A., Luo, X., Schwartz, S. B., Dubra, A., Land, M., Michaelides, M., Gardner, J. C., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.153 · Cited by 110
“With the specter of further cone cell loss from subfoveal injections or even uncertainty about loss related to the procedure, it may be prudent to consider intravitreal administration of novel vectors, such as has been shown to be effective at transducing photoreceptors in recent reports in mice and at the fovea in a…”
Mowat, F. M., Gornik, K. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., Petersen-Jones, S. M., & Bartoe, J. T. (2014) · Gene Therapy · doi:10.1038/gt.2013.64 · Cited by 108
Self-citationThompson, D. A., Ali, R. R., Banin, E., Branham, K. E., Flannery, J. G., Gamm, D. M., Hauswirth, W. W., Heckenlively, J. R., Iannaccone, A., Jayasundera, K. T., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16049 · Cited by 101
“AAV2-quad-smCBA-GFP showed effective transduction of foveal cones located where the inner retina is exceptionally thin.(53)”
Self-citationChiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 116
“The demand for intravitreal injection has ignited research on the directed evolution or design of specific capsid mutations that may lead vectors to target the outer retina via intravitreal injection [82,83].”
BackgroundMicroRNA-regulated viral vectors for gene therapy
Geisler, A., & Fechner, H. (2016) · World Journal of Experimental Medicine · doi:10.5493/wjem.v6.i2.37 · Cited by 93
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Boye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
“In addition, the inclusion of a T-V mutation on top of AAV2(quadY-F) produced a variant, AAV2(quadY-F T-V), which was capable of transducing up to 25% of photoreceptors following Ivt injection (30).”
BackgroundMethodInfluentialSelf-citationMcCullough, K. T., Boye, S. L., Fajardo, D., Calabro, K., Peterson, J. J., Strang, C. E., Chakraborty, D., Gloskowski, S., Haskett, S., Samuelsson, S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.193 · Cited by 79
“FACS Mice were euthanized, retinas were dissociated, and GFP+ PRs were collected, as previously described.(49) Immediately following sacrifice, retinas were placed in papain for dissociation (Worthington Papain Dissociation System; cat.”
MethodSelf-citationHighly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. E., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 78
Self-citationSARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration
Sasaki, Y., Kakita, H., Kubota, S., Sene, A., Lee, T. J., Ban, N., Dong, Z., Lin, J. B., Boye, S. L., DiAntonio, A., et al. (2020) · eLife · doi:10.7554/elife.62027 · Cited by 77
Self-citationScalabrino, M. L., Boye, S. L., Fransen, K. M. H., Noel, J. M., Dyka, F. M., Min, S. H., Ruan, Q., De Leeuw, C. N., Simpson, E. M., Gregg, R. G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv341 · Cited by 76
Self-citationCell and gene therapy for kidney disease
Peek, J. L., & Wilson, M. H. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00702-3 · Cited by 93
Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Kanaan, N. M., Sellnow, R. C., Boye, S. L., Coberly, B., Bennett, A., Agbandje-McKenna, M., Sortwell, C. E., Hauswirth, W. W., Boye, S. E., & Manfredsson, F. P. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.011 · Cited by 72
“AAV2 The packaging plasmid pACG2 for AAV2 (T2 WT) was mutated using site-directed mutagenesis to generate the capsid mutants as previously described.(6,18,21) Capsid tyrosine mutants (Table 1; Figures 2A and 2B) were generated by mutating Y444F (T2 1Y), Y444F+Y500F+ Y730F (T2 3Y), Y500F+Y730F (T2 2Y#1), Y444F+Y730F (T…”
MethodResultSelf-citationKhabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
“AAV vectors that are capable of efficient retinal transduction from the vitreous have been designed only recently, using rational design (Boyd et al., 2015; Boye et al., 2016; Kay et al., 2013; Petrs-Silva et al., 2011) or in vivo directed evolution (Cronin et al.”
MethodLu, Q., Ganjawala, T. H., Ivanova, E., Cheng, J. G., Troilo, D., & Pan, Z.-H. (2016) · Gene Therapy · doi:10.1038/gt.2016.42 · Cited by 70
Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances
McClements, M. E., Staurenghi, F., MacLaren, R. E., & Cehajic-Kapetanovic, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.570909 · Cited by 69
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 91
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“Compared to unmodified vectors, IVT-delivered AAV2 quad(Y-F + T-V) showed robust outer retinal transduction in mice (Kay et al., 2013) and moderate transduction in dogs (Mowat et al., 2014; Boyd et al., 2016a), but did not result in retinal transduction in sheep (Ross et al., 2020).”
BackgroundInfluentialVectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
“Photoreceptors can also be targeted via intravitreal injections of engineered AAV capsids (Cronin et al. 2014; Dalkara et al. 2013; Kay et al. 2013; Petrs-Silva et al. 2009, 2011).”
BackgroundDevelopment of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-29726-7 · Cited by 65
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 65
“2) since transduction theoretically occurs uniformly across the retina [Lebherz et al., 2008; Natkunarajah et al., 2008; Dalkara et al., 2013; Kay et al., 2013].”
BackgroundWoodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
“In a recent study, selection of a peptide incorporated into the rAAV2 capsid showed ONL transduction from the vitreous in both mice and nonhuman primates (49).”
BackgroundA versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Pandya, J., Ortiz, L., Ling, C., Rivers, A. E., & Aslanidi, G. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.74 · Cited by 55
Self-citationOptogenetic Approaches to Restoring Vision
Pan, Z., Lu, Q., Bi, A., Dizhoor, A. M., & Abrams, G. W. (2015) · Annual Review of Vision Science · doi:10.1146/annurev-vision-082114-035532 · Cited by 57
Reid, C. A., Ertel, K. J., & Lipinski, D. M. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22281 · Cited by 51
“tor) gene expression.(14) Eyes injected intravitreally with rAAV2/ 2[MAX] packaging GRK1-GFP demonstrated substantial levels of photoreceptor transduction and decreased levels of offtarget expression.”
BackgroundPromising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2015) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 49
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
Benskey, M. J., Kuhn, N. C., Galligan, J. J., Garcia, J., Boye, S. E., Hauswirth, W. W., Mueller, C., Boye, S. L., & Manfredsson, F. P. (2015) · Molecular Therapy · doi:10.1038/mt.2015.7 · Cited by 47
Self-citationBogner, B., Boye, S. L., Min, S.-H., Peterson, J. J., Ruan, Q., Zhang, Z., Reitsamer, H. A., Hauswirth, W. W., & Boye, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128759 · Cited by 48
“However, the AAV vector toolkit is rapidly expanding and by combining knowledge of AAV capsid sequences with the structures available for these serotypes [78–83] (and unpublished data), it is now possible to delineate determinants of vector function (both intracellular and extracellular) and to rationally design vecto…”
BackgroundSelf-citationGene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 47
“Quadruple and pentuple tyrosine mutant AAV2/2 vectors provided the first proof of concept of the feasibility of outer retina transduction from the vitreous in mice.(45,46) More recently, Dalkara and co-workers used an in vivo directed evolution approach to select an AAV2/2 variant (7m8) that was able to transduce mous…”
Backgroundkleine Holthaus, S.-M., Ribeiro, J., Abelleira-Hervas, L., Pearson, R. A., Duran, Y., Georgiadis, A., Sampson, R. D., Rizzi, M., Hoke, J., Maswood, R., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.027 · Cited by 45
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
Gene Augmentation for adRP Mutations in RHO
Lewin, A. S., Rossmiller, B., & Mao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017400 · Cited by 43
“Although novel capsid variants may permit infection of photoreceptor cells following intravitreal injection (Dalkara et al. 2013; Kay et al. 2013), the inner limiting membrane would prevent transduction of rod cells in the peripheral retina.”
BackgroundInfluentialIldefonso, C. J., Jaime, H., Brown, E. E., Iwata, R. L., Ahmed, C. M. I., Massengill, M. T., Biswal, M. R., Boye, S. L., Hauswirth, W. W., Ash, J. D., et al. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17703 · Cited by 43
“This mutant variation of AAV2 has been shown to transduce many cell types within the retina after an intravitreal injection.(31)”
BackgroundSelf-citationBlue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
Luo, X., Cideciyan, A. V., Iannaccone, A., Román, A. J., Ditta, L. C., Jennings, B., Yatsenko, S. A., Sheplock, R., Sumaroka, A., Świder, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125700 · Cited by 40
“The limitation of intravitreal delivery in a retina-wide cone disease is that the only retinal area receiving treatment is likely to be the foveal region [41,42].”
BackgroundPhotoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs
Boyd, R. F., Sledge, D. G., Boye, S. L., Boye, S. E., Hauswirth, W. W., Komáromy, A. M., Petersen-Jones, S. M., & Bartoe, J. T. (2016) · Gene Therapy · doi:10.1038/gt.2015.96 · Cited by 38
Self-citationBoyd, R. F., Boye, S. L., Conlon, T. J., Erger, K. E., Sledge, D. G., Langohr, I. M., Hauswirth, W. W., Komáromy, A. M., Boye, S. E., Petersen-Jones, S. M., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.31 · Cited by 37
Self-citationEngineered Capsids for Efficient Gene Delivery to the Retina and Cornea
Frederick, A., Sullivan, J., Liu, L., Adamowicz, M., Lukason, M., Raymer, J., Luo, Z., Jin, X., Rao, K. N., & O'Riordan, C. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.070 · Cited by 35
“48 Thus, the effect of altering surface charge on the AAV5 capsid was explored to determine if improved transduction activity in the retina could be achieved, both in the context of intravitreal and subretinal delivery.”
Corneal Regeneration Using Gene Therapy Approaches
Sarkar, S., Panikker, P., D’Souza, S., Shetty, R., Mohan, R. R., & Ghosh, A. (2023) · Cells · doi:10.3390/cells12091280 · Cited by 40
“A study showed efficient transduction of mouse photoreceptors when four surface tyrosine residues and one surface threonine residue were mutated (Y272F, Y444F, Y500F, Y730F, T491V) [215].”
BackgroundChen, M., Maeng, K., Nawab, A., Francois, R. A., Bray, J. K., Reinhard, M. K., Boye, S. L., Hauswirth, W. W., Kaye, F. J., Aslanidi, G., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.089 · Cited by 42
Self-citationDevelopment of novel AAV serotype 6 based vectors with selective tropism for human cancer cells
Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., & Aslanidi, G. (2015) · Gene Therapy · doi:10.1038/gt.2015.89 · Cited by 40
Self-citationA novel retinal ganglion cell promoter for utility in AAV vectors
Hanlon, K. S., Chadderton, N., Palfi, A., Blanco Fernandez, A., Humphries, P., Kenna, P. F., Millington-Ward, S., & Farrar, G. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00521 · Cited by 34
“, 2013), rhodopsin kinase (Khani et al., 2007; Boye et al., 2010; Sun et al., 2010; Kay et al., 2013; Molday et al., 2013), RPE65 (Bainbridge et al.”
BackgroundTeo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
Gene Delivery of a Viral Anti-Inflammatory Protein to Combat Ocular Inflammation
Ildefonso, C. J., Jaime, H., Rahman, M. M., Li, Q., Boye, S. L., Hauswirth, W. W., Lucas, A., McFadden, G., & Lewin, A. S. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.089 · Cited by 33
Self-citationDa Costa, R., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 32
Krotova, K. Y., Day, A., & Aslanidi, G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.001 · Cited by 31
Self-citationCehajic-Kapetanovic, J., Milosavljevic, N., Bedford, R. A., Lucas, R. J., & Bishop, P. N. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.002 · Cited by 30
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“…exclusive AAV-mediated expression in photoreceptor cells via subretinal injection in mice and NHPs with unexpected off-target expression in RGCs. 20 In another study, AAV2/5 viral vector containing GRK1 promoter was utilized to rescue rods and cones from degeneration and retention of vision in…”
De Silva, S. R., Charbel Issa, P., Singh, M. S., Lipinski, D. M., Barnea-Cramer, A. O., Walker, N. J., Barnard, A. R., Hankins, M. W., & MacLaren, R. E. (2016) · Gene Therapy · doi:10.1038/gt.2016.54 · Cited by 29
“efforts are ongoing to improve AAV transduction efficacy and alter cell tropism (8-10).”
BackgroundA Drug-Tunable Gene Therapy for Broad-Spectrum Protection against Retinal Degeneration
Santiago, C. P., Keuthan, C. J., Boye, S. L., Boye, S. L., Imam, A. A., & Ash, J. D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.016 · Cited by 31
Self-citationGene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Human L- and M-opsins restore M-cone function in a mouse model for human blue cone monochromacy.
Deng, W., Li, J., Zhu, P., Chiodo, V. A., Smith, W. C., Freedman, B., Baehr, W., Pang, J., & Hauswirth, W. W. (2018) · PubMed Central · Cited by 29
Self-citationLee, S. H., Yang, J. Y., Madrakhimov, S. B., Park, H. Y., Park, K., & Park, T. K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.008 · Cited by 29
“Previous studies using intravitreal delivery of a low dose of AAV (10(9) 10(10) vg/mL) have shown sufficient transduction in various conditions of the retina.(14,54,55) Hence, we used similar AAV concentration to minimize unexpected adverse events due to unnecessarily high vector dose usage in this study.”
MethodMurray, S. J., Russell, K. N., Melzer, T. R., Gray, S. J., Heap, S. J., Palmer, D. N., & Mitchell, N. L. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108600 · Cited by 32
AAV2 Delivery of Flt23k Intraceptors Inhibits Murine Choroidal Neovascularization
Zhang, X., Das, S. K., Passi, S. F., Uehara, H., Bohner, A. D., Chen, M., Tiem, M., Archer, B. J., & Ambati, B. K. (2014) · Molecular Therapy · doi:10.1038/mt.2014.199 · Cited by 29
Kellish, P. C., Marsic, D., Crosson, S. M., Choudhury, S., Scalabrino, M. L., Strang, C. E., Hill, J. L., McCullough, K. T., Peterson, J. J., Fajardo, D. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.001 · Cited by 28
“4,29 Since our library is AAV2-Figure Scale bar, 100 m m (white, bottom right).”
InfluentialSelf-citationDu, W., Tao, Y., Deng, W., Zhu, P., Li, J., Dai, X., Zhang, Y., Shi, W., Liu, X., Chiodo, V. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv114 · Cited by 30
“The construct was packaged into serotypes 5 and 8 (Y447, 733F), which was originally made in Boye’s lab (38).”
BackgroundSelf-citationDirected evolution of adeno-associated virus 5 capsid enables specific liver tropism
Wang, Y., Yang, C., Hu, H., Chen, C., Yan, M., Ling, F., Wang, K. C., Wang, X., Deng, Z., Zhou, X., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.017 · Cited by 27
Prdm1 overexpression causes a photoreceptor fate-shift in nascent, but not mature, bipolar cells
Goodson, N., Park, K. U., Silver, J. S., Chiodo, V. A., Hauswirth, W. W., & Brzezinski, J. A. (2020) · Developmental Biology · doi:10.1016/j.ydbio.2020.06.003 · Cited by 26
Self-citationGaroon, R. B., & Stout, J. T. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000256 · Cited by 25
AAV- based vector improvements unrelated to capsid protein modification
Shitik, E. M., Shalik, I. K., & Yudkin, D. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1106085 · Cited by 30
“In intravitreal injection, the modified vectors were detected to suppress transgene expression in all cells except photoreceptors (87).”
BackgroundProstaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats
Chern, K. J., Nettesheim, E. R., Reid, C. A., Li, N. W., Marcoe, G. J., & Lipinski, D. M. (2022) · Communications Biology · doi:10.1038/s42003-022-04134-w · Cited by 25
Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection
Lipinski, D. M., Reid, C. A., Boye, S. L., Peterson, J. J., Qi, X., Boye, S. L., Boulton, M. E., & Hauswirth, W. W. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.097 · Cited by 25
Self-citationPAX6 MiniPromoters drive restricted expression from rAAV in the adult mouse retina
Hickmott, J. W., Chen, C., Arenillas, D. J., Korecki, A. J., Lam, S. L., Molday, L. L., Bonaguro, R. J., Zhou, M., Chou, A., Mathelier, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.51 · Cited by 26
Self-citationConcepts and Strategies in Retinal Gene Therapy
Aguirre, G. D. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22978 · Cited by 25
“Some newer AAV vectors have single or multiple mutations that replace critical capsid tyrosine residues to enhance nuclear targeting by bypassing ubiquitination and proteasomal degradation.(63,64) These vector constructs also can be packaged as self-complementary vectors to avoid delays caused by DNA synthesis, as mus…”
Sun, S., & Schaffer, D. V. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.12.011 · Cited by 24
Basche, M., Kampik, D., Kawasaki, S., Branch, M. J., Robinson, M. R., Larkin, F., Smith, A. J., & Ali, R. R. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.115 · Cited by 23
“46,47 This requires the AAV virion to penetrate the inner limiting membrane and * 200 l m of neural tissue, which several engineered serotypes have now been shown capable of doing.”
Ildefonso, C. J., Jaime, H., Biswal, M. R., Boye, S. L., Li, Q., Hauswirth, W. W., & Lewin, A. S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.30 · Cited by 20
Self-citationDai, X., He, Y., Zhang, H., Zhang, Y., Liu, Y., Wang, M., Chen, H., & Pang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188032 · Cited by 22
Antiangiogenic Eye Gene Therapy
Corydon, T. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.064 · Cited by 21
“30,32 Novel primate-derived hybrid recombinant AAV serotypes providing shuffled AAV capsid domains are also gaining more ground in clinical applications in the case of vector retreatment.”
Lee, S. H., Kim, Y.-S., Nah, S. K., Kim, H. J., Park, H. Y., Yang, J. Y., Park, K., & Park, T. K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.008 · Cited by 19
Kay, C. N., Ryals, R. C., Aslanidi, G., Min, S.-H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D. T., Ayala, A. E., Vliet, K. V., et al. (2013) · PLoS ONE · doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a · Cited by 18
Self-citationSong, H., Bush, R. A., Zeng, Y., Qian, H., Wu, Z., & Sieving, P. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.006 · Cited by 17
A Modified Arrestin1 Increases Lactate Production in the Retina and Slows Retinal Degeneration
Nelson, T. S., Simpson, C. P., Dyka, F. M., Dinculescu, A., & Smith, W. C. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.272 · Cited by 18
“In each case, the transgene was packaged into an AAV2-based vector containing four tyrosine-to-phenylalanine (Y272, 444, 500, 730F) plus one threonine-to-valine substitution (T491V) in the capsid, which has been shown to have excellent penetration of the murine retina and transduction of photoreceptors when delivered…”
MethodSelf-citationWatson, Z. L., Ertel, M. K., Lewin, A. S., Tuli, S. S., Schultz, G. S., Neumann, D. M., & Bloom, D. C. (2016) · Journal of Virology · doi:10.1128/jvi.01028-16 · Cited by 18
Crosson, S. M., Bennett, A., Fajardo, D., Peterson, J. J., Zhang, H., Li, W., Leahy, M. T., Jennings, C. K., Boyd, R. F., Boye, S. L., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02440-20 · Cited by 16
“Injections were performed under a Leica M80 stereomicroscope as previously reported (27, 65).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Kay, C. N., Ryals, R. C., Aslanidi, G. V., Min, S. H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D., Ayala, A. E., Van Vliet, K., Agbandje-McKenna, M., Hauswirth, W. W., Boye, S. L., & Boye, S. E.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Boye, Shannon E.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-26
- Volume
- 8
- Issue
- 4
- Pages
- e62097
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3637363
- OpenAlex
- W2067733824
- Cited by
- 168
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2023: 7 · 2022: 11 · 2021: 14 · 2020: 17 · 2019: 16 · 2018: 19 · 2017: 14 · 2016: 21 · 2015: 24 · 2014: 11 · 2013: 5
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Update notices
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Foundation Fighting Blindness
- Research to Prevent Blindness
- National Eye Institute (P30EY021721, R01EY017549, R24EY022012)
- National Institute of General Medical Sciences (R01GM082946)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, capsid mutations, phototransduction, intravitreal delivery, retinal gene therapy, AAV2, AAV5, AAV8, off-target expression, cone photoreceptors, rod photoreceptors
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Line, Chickens, Genetic Vectors, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Promoter Regions, Genetic, Serotyping, Transduction, Genetic, Gene Expression, Gene Transfer Techniques, Transgenes, Photoreceptor Cells, Vertebrate, MicroRNAs, Mice, G-Protein-Coupled Receptor Kinase 1, Viral Tropism, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.